MA34077B1 - Nouveau peptides et procedes pour leur preparation, ain que leur utilisation - Google Patents

Nouveau peptides et procedes pour leur preparation, ain que leur utilisation

Info

Publication number
MA34077B1
MA34077B1 MA35233A MA35233A MA34077B1 MA 34077 B1 MA34077 B1 MA 34077B1 MA 35233 A MA35233 A MA 35233A MA 35233 A MA35233 A MA 35233A MA 34077 B1 MA34077 B1 MA 34077B1
Authority
MA
Morocco
Prior art keywords
glucagon
gip
preparation
well
gluc
Prior art date
Application number
MA35233A
Other languages
Arabic (ar)
English (en)
Inventor
Jorge Alsina-Fernandez
Krister Bengt Bokvist
Lili Guo
John Philip Mayer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44041636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34077(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA34077B1 publication Critical patent/MA34077B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur le domaine du traitement du diabète et concerne des peptides qui présentent une activité pour, à la fois, le récepteur du peptide insulinotrope dépendant du glucose (gip-r) et le récepteur du peptide-1 de type glucagon (glp-1-r) et qui leur sont sélectifs par rapport au récepteur du glucagon (gluc-r). Plus précisément, l'invention concerne des analogues de gip avec des substitutions d'acide aminé introduites pour moduler l'activité d'à la fois gip-r et de glp-1-r et pour maintenir une sélectivité par rapport à gluc-r.
MA35233A 2010-03-26 2011-03-23 Nouveau peptides et procedes pour leur preparation, ain que leur utilisation MA34077B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31785010P 2010-03-26 2010-03-26
PCT/US2011/029501 WO2011119657A1 (fr) 2010-03-26 2011-03-23 Nouveaux peptides et procédés pour leur préparation et utilisation

Publications (1)

Publication Number Publication Date
MA34077B1 true MA34077B1 (fr) 2013-03-05

Family

ID=44041636

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35233A MA34077B1 (fr) 2010-03-26 2011-03-23 Nouveau peptides et procedes pour leur preparation, ain que leur utilisation

Country Status (26)

Country Link
US (1) US8815811B2 (fr)
EP (1) EP2552471B1 (fr)
JP (1) JP5887335B2 (fr)
KR (1) KR101407775B1 (fr)
CN (1) CN102821779B (fr)
AR (1) AR080592A1 (fr)
AU (1) AU2011232597B2 (fr)
BR (1) BR112012024373A2 (fr)
CA (1) CA2794664A1 (fr)
CL (1) CL2012002635A1 (fr)
CO (1) CO6630128A2 (fr)
CR (1) CR20120457A (fr)
DO (1) DOP2012000244A (fr)
EA (1) EA022489B1 (fr)
EC (1) ECSP12012181A (fr)
ES (1) ES2568796T3 (fr)
GT (1) GT201200263A (fr)
MA (1) MA34077B1 (fr)
MX (1) MX2012011127A (fr)
PE (1) PE20130523A1 (fr)
PH (1) PH12012501899A1 (fr)
SG (1) SG184289A1 (fr)
TN (1) TN2012000432A1 (fr)
TW (1) TWI535450B (fr)
WO (1) WO2011119657A1 (fr)
ZA (1) ZA201206832B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2008086086A2 (fr) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Analogues de glucagon présentant une solubilité améliorée dans des tampons à ph physiologiques
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
CA2702289A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composes presentant une activite d'antagoniste de glucagon et d'agoniste du glp-1
EP2217701B9 (fr) 2007-10-30 2015-02-18 Indiana University Research and Technology Corporation Antagonistes du glucagon
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
WO2011075393A2 (fr) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
EP2569000B1 (fr) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone
EP2588126A4 (fr) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp Promédicaments peptidiques à base d'amides de la superfamille du glucagon
CA2821766A1 (fr) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Analogues du glucagon presentant une activite de recepteur de gip
EA031230B1 (ru) 2011-06-22 2018-12-28 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты глюкагонового рецептора/glp-1-рецептора
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
CA2847246A1 (fr) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Peptides de la superfamille du glucagon presentant une action sur les recepteurs aux glucocorticoides
WO2013164483A1 (fr) 2012-05-03 2013-11-07 Zealand Pharma A/S Composés agonistes doubles du gip-glp-1 et méthodes
AR091422A1 (es) 2012-06-14 2015-02-04 Sanofi Sa Analogos peptidicos de la exendina 4
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) * 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
ES2623979T3 (es) 2013-03-21 2017-07-12 Sanofi-Aventis Deutschland Gmbh Síntesis de productos peptídicos que contienen hidantoína
ES2624961T3 (es) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Síntesis de productos de péptido que contienen imida cíclica
AR095986A1 (es) 2013-04-03 2015-11-25 Sanofi Sa Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
PL2986313T3 (pl) * 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
LT3004155T (lt) 2013-05-28 2021-12-27 Takeda Pharmaceutical Company Limited Peptidų junginys
SI3057984T1 (sl) 2013-10-17 2018-10-30 Zealand Pharma A/S Acilirani glukagonski analogi
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
US10093713B2 (en) * 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086730A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 non acylés
WO2015086729A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs glp-1/gip
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
EP3151852A1 (fr) 2014-06-04 2017-04-12 Novo Nordisk A/S Co-agonistes de récepteur du glucagon/glp-1 à usage médical
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN109477094B (zh) 2016-05-24 2022-04-26 武田药品工业株式会社 肽化合物
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
WO2019140030A1 (fr) 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
EP3699187A1 (fr) * 2019-02-21 2020-08-26 Universite D'angers Peptide ciblant les récepteurs du gip et du glp-2 pour le traitement de troubles osseux
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
MX2022009149A (es) * 2020-01-23 2022-12-15 Lilly Co Eli Compuestos coagonistas de gip/glp1.
JP7544838B2 (ja) 2020-03-06 2024-09-03 サノフイ 選択的ｇｉｐ受容体アゴニストとしてのペプチド
JP7526804B2 (ja) * 2020-03-11 2024-08-01 エニジェン カンパニー リミテッド 新規化合物を含む抗糖尿病及び抗肥満用組成物
CN117866048A (zh) * 2021-05-28 2024-04-12 广东众生睿创生物科技有限公司 多肽的制备及其应用
WO2022253202A1 (fr) * 2021-06-01 2022-12-08 南京知和医药科技有限公司 Dérivé polypeptidique ayant un effet d'activation à double cible de glp-1r et de gipr, procédé de préparation associé et son utilisation
CA3230915A1 (fr) 2021-09-06 2023-03-09 Thomas Boehme Nouveaux peptides utilises en tant qu'agonistes puissants et selectifs du recepteur de gip
KR20230037391A (ko) * 2021-09-09 2023-03-16 애니젠 주식회사 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2023088140A1 (fr) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 Peptide agrafé et son utilisation
CA3262093A1 (fr) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Formulations pharmaceutiques et méthodes pour le traitement de troubles métaboliques et hépatiques
JP2025531200A (ja) 2022-09-15 2025-09-19 イーライ リリー アンド カンパニー Ｇｉｐ及びｇｌｐ－１二重アゴニスト化合物
AU2023415591A1 (en) 2022-12-30 2025-08-14 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
EP4714434A1 (fr) 2023-05-19 2026-03-25 Aulbio Co., Ltd. Microsphère comprenant du tirzépatide, son procédé de préparation, et composition pharmaceutique la comprenant
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
TW202517291A (zh) 2023-06-30 2025-05-01 丹麥商西蘭製藥公司 組合療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2006121904A1 (fr) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Agonistes du recepteur du polypeptide insulinotropique gluco-dependant (gip) et procedes pharmacologiques d'utilisation associes
WO2006121860A2 (fr) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation
BRPI0915282A2 (pt) * 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
EP2328922A4 (fr) * 2008-08-07 2013-01-02 Ipsen Pharma Sas Analogues de polypeptide insulinotrope glucose-dépendant
BRPI0917580A2 (pt) * 2008-08-07 2016-10-11 Ipsen Pharma Sas composto, composição farmacêutica, métodos para elicitar um efeito agonista e antagonista de um receptor de gip, para tratar condições ou doenças mediadas por ligação de receptor de gip, para tratar diabetes, para tratar distúrbios relacionados com diabete, para tratar ou previnir causas secundárias de diabete para tratar obesidade, e para estimular secreção de insulina, e, uso de um análogo de peptídeo
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения

Also Published As

Publication number Publication date
ES2568796T3 (es) 2016-05-04
PH12012501899A1 (en) 2013-01-14
JP5887335B2 (ja) 2016-03-16
AR080592A1 (es) 2012-04-18
CL2012002635A1 (es) 2012-12-21
EP2552471A1 (fr) 2013-02-06
AU2011232597A1 (en) 2012-08-30
TW201201829A (en) 2012-01-16
KR20120133402A (ko) 2012-12-10
AU2011232597B2 (en) 2015-01-29
WO2011119657A1 (fr) 2011-09-29
CN102821779B (zh) 2015-03-11
GT201200263A (es) 2013-12-05
DOP2012000244A (es) 2013-02-15
BR112012024373A2 (pt) 2017-01-10
CO6630128A2 (es) 2013-03-01
KR101407775B1 (ko) 2014-06-17
SG184289A1 (en) 2012-11-29
CN102821779A (zh) 2012-12-12
MX2012011127A (es) 2012-10-15
ECSP12012181A (es) 2012-11-30
TWI535450B (zh) 2016-06-01
ZA201206832B (en) 2014-03-26
EA201270723A1 (ru) 2013-01-30
CR20120457A (es) 2012-10-16
EA022489B1 (ru) 2016-01-29
US20110237503A1 (en) 2011-09-29
US8815811B2 (en) 2014-08-26
PE20130523A1 (es) 2013-04-25
TN2012000432A1 (en) 2014-01-30
CA2794664A1 (fr) 2011-09-29
EP2552471B1 (fr) 2016-03-16
JP2013523647A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
MA34077B1 (fr) Nouveau peptides et procedes pour leur preparation, ain que leur utilisation
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
EA201690660A1 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
CY1119283T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
NZ612297A (en) Glucagon analogs exhibiting gip receptor activity
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
EA201690494A1 (ru) Ацилированные аналоги глюкагона
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
PH12015500531A1 (en) Glucagon analogues
MX2013013913A (es) Polipeptidos.
MX2014014946A (es) Uso de peptidos glp-1 de accion prolongada.
MX365458B (es) Agonistas de glucagon/peptido similiar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
PH12012502461A1 (en) Glucagon analogues
EA202090593A2 (ru) Пептидное соединение
BR112013003522A2 (pt) "polipeptídeos relaxina modificados compreendeendo um aminoácido não codificado naturalmente, uso, método de preparação, bem como ácido nucleico codificando os mesmos"
MX386803B (es) Agonistas de receptor de glp-1/glucagón de acción prolongada.
MX2014005108A (es) Constructos de polipeptidos y sus usos.
BR112015031040A8 (pt) Novos moduladores do receptor de glp-1
MX2015015188A (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
AR083528A1 (es) Analogos de peptido insulinotropico dependiente de glucosa
UA113977C2 (xx) Фармацевтична композиція з покращеною стабільністю